Researchers compared the risk for serious infections in offspring of mothers with chronic inflammatory diseases who received non-TNFi biologics or tofacitinib during pregnancy vs offspring who were unexposed, but exposed to TNFi in utero.
Your search for tofacitinib returned 22 results
Case reports describe repigmentation of vitiligo with facial involvement in Hispanic woman, white man
Tofacitinib is superior for patients with inadequate response to TNF inhibitors or conventional DMARDs
The researchers found that significantly more patients receiving tofacitinib 5mg and tofacitinib 10mg versus placebo achieved a ≥50% reduction in the Nail Psoriasis Severity Index (NAPSI) score from baseline (NAPSI50)
A total of 18.5% patients taking tofacitinib experienced a remission of their condition in 8 weeks compared to just 8.2% of patients receiving placebo.
Tofacitinib is superior to methotrexate in treating rheumatoid arthritis, but increased side effects were seen with tofacitinib, including development of herpes zoster.
The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs).
Tofacitinib slows the progression of joint damage and improves disease activity in patients with rheumatoid arthritis (RA).
Tofacitinib, an oral inhibitor of Janus kinase 1, 2, and 3, can reduce disease severity and induce remission better than a placebo in patients with moderately to severely active ulcerative colitis.
For patients with rheumatoid arthritis, a novel oral Janus kinase inhibitor, tofacitinib, is associated with reduced symptoms when used as monotherapy or in addition to background methotrexate.